

Docket No. A015/US CON2

IN RE U.S. PATENT APPLICATION
SERIAL NUMBER 10/015,832

RECEIVED
CENTRAL FAX CENTER

TRANSMITTAL COVER LETTER FOR FACSIMILE TRANSMISSION

APR 08 2004

PLEASE DELIVER THE FOLLOWING PAGES TO:

Hon. Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Attention: Examiner Phillip Gambel
Group Art Unit: 1644
Confirmation No.: 1235

OFFICIAL

TELECOPIER NUMBER: (703) 872-9306


THE SENDER IS: Margaret A. Pierri
Registration No. 30,709
c/o FISH & NEAVE
1251 Avenue of the Americas
New York, New York 10020
Tel.: (212) 596-9000
Fax: (212) 597-9090

CLIENT NO. 000455.0091

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted
to the U.S. Patent and Trademark Office on the date shown below.

April 8, 2004
Date


Claire J. Saint-Jean Goodman

TOTAL NUMBER OF PAGES, INCLUDING COVER LETTER: 9
WE ARE TRANSMITTING FROM XEROX 7021.

DATE: 4/8/04

TIME: _____

TELECOPIER OPERATOR: Claine

PLEASE ACKNOWLEDGE SAFE RECEIPT OF THIS TRANSMISSION BY SIGNING
AND RETURNING THIS COVER SHEET TO US BY FACSIMILE.

WE ACKNOWLEDGE SAFE RECEIPT OF THIS TRANSMISSION.

SIGNED: _____

DATE: _____

IF NOT, PLEASE CALL BACK AS SOON AS POSSIBLE.

PHONE: (212) 596-9300 (ASK FOR "TELECOPIER")

Docket No.: A015/US CON2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Phillip Gambel
Group Art Unit : 1644
Applicants : Susan L. Kalled et al.
Application No. : 10/015,832 Confirmation No.: 1235
Filed : December 12, 2001
For : METHOD OF THERAPEUTIC ADMINISTRATION OF
ANTI-CD40L COMPOUNDS

New York, New York
April 8, 2004

Hon. Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450


TRANSMITTAL LETTER

Sir:

Transmitted herewith: [X] Response to Restriction
Requirement; to be filed in the above-identified patent
application.

The Director is hereby authorized to charge any additional fee due, or credit any overpayment, in connection with this Letter, to Deposit Account No. 06-1075. A duplicate copy of this Letter is enclosed herewith.

Respectfully submitted,



Margaret A. Pierri (Reg. No. 30,709)
Attorney for Applicants
Shawn-Marie Mayrand (Reg. No. 48,986)
Agent for Applicants
c/o FISH & NEAVE
Customer No. 1473
1251 Avenue of the Americas
New York, New York 10020-1104
Tel.: (212) 596-9000
Fax.: (212) 596-9090

Docket No.: A015/US CON2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
CENTRAL FAX CENTER

APR 08 2004

OFFICIAL

Examiner : Phillip Gambel
Group Art Unit : 1644
Applicants : Susan L. Kalled et al.
Application No. : 10/015,832 Confirmation No.: 1235
Filed : December 12, 2001
For : METHOD OF THERAPEUTIC ADMINISTRATION OF
ANTI-CD40L COMPOUNDS

New York, New York
April 8, 2004

Hon. Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT

Sir:

This responds to the March 10, 2004 Office Action
- Restriction Requirement, issued in the above-identified
application.

The Examiner has required restriction of the
claims of this application under 35 U.S.C. § 121 into one
of the following three groups:

I. Claims 1-17, drawn to methods of treating an antibody-related disease, an autoimmune disease or a chronic immune system disorder inflammation with CD40L-specific compounds, classified in Class 424, subclass 130.1.

II. Claims 18-23, drawn to methods of inhibiting transplant rejection with CD40L-specific compounds, classified in Class 424, subclass 130.1.

III. Claim 24, drawn to methods of suppressing an immune reaction to a transgene product with CD40L-specific compounds, classified in Class 424, subclass 130.1.

The Examiner contends that "[i]nventions I, II, and III are different methods which require different ingredients, process steps and endpoints. Therefore, they are patentably distinct."

Applicants elect, with traverse, the Group I claims (claims 1-17), drawn to methods of treating an antibody-related disease, an autoimmune disease or a chronic immune system disorder inflammation with CD40L-specific compounds. Applicants make this election of the Group I claims expressly without waiver of their right to file divisional or continuing applications claiming priority and benefit from this application under 35 U.S.C. § 120 and directed to the non-elected subject matter.

The Examiner further states that the application contains claims directed to the following patentably distinct species of the claimed Group I, wherein the

antibody-related disease, autoimmune disease or a chronic immune system disorder inflammation condition is:


- A. SLE,
- B. myasthenia gravis,
- C. autoimmune hemolytic anemia,
- D. ITP,
- E. anti-phospholipid syndrome,
- F. psoriasis,
- G. allergy,
- H. arthritis or
- I. multiple sclerosis.

The Examiner contends that "[t]hese species are distinct because the pathological conditions differ in etiologies and therapeutic endpoints." Accordingly, the Examiner asserts that a further election of species is required, under 35 U.S.C. § 121, in the event that no generic claim is finally held to be allowable. Currently, claim 1 has been deemed generic.

Applicants elect, with traverse, the subject matter of species A - SLE (systemic lupus erythematosis). The claims reading on this species include independent claims 1, 4, 6 and 9 with respect to SLE (systemic lupus erythematosis), and dependent claims 2, 3, 5, 7, 8, 10, 11, and 13-17, to the extent that they refer back to claim 1, 4, 6 or 9, to the extent that those claims read on treatment of patients with SLE. Applicants make this election expressly without waiver of their right to file for and obtain claims directed to the non-elected subject

matter in divisional or continuing applications claiming
benefit herefrom under 35 U.S.C. § 120.

Respectfully submitted,



Margaret A. Pierri (Reg. No. 30,709)
Attorney for Applicants
Shawn-Marie Mayrand (Reg. No. 48,986)
Agent for Applicants
c/o FISH & NEAVE
Customer No. 1473
1251 Avenue of the Americas
New York, New York 10020-1104
Tel.: (212) 596-9000
Fax.: (212) 596-9090